You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
The study may shed light on an ideal biomarker strategy for the antibody drug conjugate, which Sutro is exploring in ovarian and endometrial cancers.
A recent paper details how, across several cancer types, high TMB is associated with improved outcomes with immunotherapy but worse outcomes without it.
FLEX will include full transcriptome data paired with 800 data points from 10,000 patients, offering researchers the chance to study diverse patient subsets.
An exploratory analysis in the ASCENT study showed improved survival with Gilead's antibody-drug conjugate regardless of patients' biomarker status.
Kymriah and Yescarta were evaluated in indolent NHL subtypes, and Yescarta was evaluated in the front-line setting for high-risk large B-cell lymphoma.
The study found that being Black was an independent predictor of poor survival and suggested that mutation status in genes such as NPM1 may play a role in the disparities.
Persephone Biosciences has launched a prospective, longitudinal study to evaluate 4,000 patients' gut microbiomes and link them with cancer treatment response.
This is the second precision oncology drug approved by the agency for patients with RET-mutant medullary thyroid cancer or RET fusion-positive thyroid cancer.
With the PARIS test, researchers identified several targeted agents that could help patients overcome PARP inhibitor resistance and may be worth further study.
Researchers found that cancer patients with BRCA2 mutations respond particularly well to checkpoint inhibitors compared to those with BRCA1 mutations.